ConductScience.org, home

Gene · 10800

CYSLTR1: cysteinyl leukotriene receptor 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. CYSLTR1: cysteinyl leukotriene receptor 1. Genes, record 10800. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10800

On this page

Gene

Symbol
CYSLTR1
HGNC
Name
cysteinyl leukotriene receptor 1
HGNC
NCBI Gene ID
10800
NCBI Gene
HGNC ID
HGNC:17451
HGNC
Ensembl
ENSG00000173198
NCBI Gene
Aliases
CYSLT1, CYSLT1R, CYSLTR, CysLT(1), CysLT1, HMTMF81
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9Y271Cysteinyl leukotriene receptor 13372Ensembl, GeneID, HGNC

Source UniProt

Patents46

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1442746Q9Y271Espacenet
EP 4641201 A22025-10-299521Q9Y271Espacenet
JP 2025529142 A2025-09-041206Q9Y271Espacenet
US 12371689 B22025-07-291206Q9Y271Espacenet
JP 2025517969 A2025-06-129521Q9Y271Espacenet
US 11446398 B22022-09-2021624Q9Y271Espacenet
US 11446398 B22022-09-2021625Q9Y271Espacenet
US 11400116 B22022-08-023534Q9Y271Espacenet
JP 2022524081 A2022-04-27124595Q9Y271Espacenet
JP 2022524081 A2022-04-27124596Q9Y271Espacenet

1 to 10 of 46

See all 46 patents

Drugs6

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
CR-3465CHEMBL5314389Cysteinyl leukotriene receptor 1 antagonistANTAGONISTChEMBL
CR-3465 FREE ACIDCHEMBL5316169Cysteinyl leukotriene receptor 1 antagonistANTAGONISTChEMBL
MONTELUKASTCHEMBL787Cysteinyl leukotriene receptor 1 antagonistANTAGONISTChEMBL
MONTELUKAST SODIUMCHEMBL1200681Cysteinyl leukotriene receptor 1 antagonistANTAGONISTChEMBL
PRANLUKASTCHEMBL21333Cysteinyl leukotriene receptor 1 antagonistANTAGONISTChEMBL
ZAFIRLUKASTCHEMBL603Cysteinyl leukotriene receptor 1 antagonistANTAGONISTChEMBL

Trials209

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07537868MONTELUKASTPHASE2ClinicalTrials.gov
NCT07532993MONTELUKASTPHASE4ClinicalTrials.gov
NCT07409714MONTELUKASTEARLY_PHASE1ClinicalTrials.gov
NCT07101640MONTELUKASTPHASE1/PHASE2ClinicalTrials.gov
NCT06887673MONTELUKASTEARLY_PHASE1ClinicalTrials.gov
NCT06747130MONTELUKASTPHASE2/PHASE3ClinicalTrials.gov
NCT06597682MONTELUKASTClinicalTrials.gov
NCT06340984MONTELUKASTPHASE3ClinicalTrials.gov
NCT06113640MONTELUKASTPHASE2/PHASE3ClinicalTrials.gov
NCT05959889MONTELUKASTClinicalTrials.gov

1 to 10 of 209

See all 209 trials

NIH grants774

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleCYSLTR1 papersNewest fiscal year
R01AI078908Control of Pulmonary Inflammation by Leukotriene E4212025
U19AI095219Pathophysiologic and Therapeutic Mechanisms of Aspirin Exacerbated Respiratory Disease192025
T32AI007306Immunologic Basis of Resistance and Hypersensitivity122025
R01AI136041Eicosanoid Networks in Aspirin Hypersensitivity82025
U19AI070535Airway Inflammation and Airway Remodeling in Severe Asthma72025
R01HL058506G Protein-Coupled Receptor Regulation in Airway Myocytes62025
U19AI095227Viral and Host Determinants of Infant and Childhood Allergy and Asthma42025
I01BX005073Targeting pathogenic innate lymphoid cells in airway disease32025
P30CA008748Cancer Center Support Grant32025
R01AI134989Type 2 Inflammation and Remodeling Elicited Through an LTE4/OXGR1-dependent pathway32025

1 to 10 of 774Source NIH's project files

See all 774 nih grants

Papers1,455

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
A CotB1p-mediated one-step immobilization strategy for constructing GPCR affinity chromatography to screen multi-target natural product ligands.J Pharm Biomed Anal202742800465PubTator, text miningPubMed
Author Correction: RNA-binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation and inflammation partially through CysLT1R.Nat Commun202642791265PubTator, text miningPubMed
Assessment of the binding characteristics of three antagonists toward CysLTR1 by affinity chromatography.J Chromatogr B Analyt Technol Biomed Life Sci202642705206PubTator, text miningPubMed
Neuroinflammation- molecular target based therapeutic approach.Adv Protein Chem Struct Biol202642448410PubTator, text miningPubMed
Targeted CysLTR1 Blockade Rescues Myeloid-Mediated Resistance to Immune Checkpoint Inhibition in Solid Malignancies: A Combined Genomic, Emulated Clinical Trial, and Epidemiological Negative-Control Analysis.
Am J Clin Oncol202642418282PubTator, text miningPubMed
Redox-sensitive GPCR signaling drives Gq-dependent Ca2+ mobilization and cytokine production in human bronchial epithelial cells.Am J Physiol Cell Physiol202642314770PubTator, text miningPubMed
Integrated machine learning and multi-omics analysis identifies ALOX5 as a potential therapeutic target for tubulointerstitial inflammation in diabetic kidney disease.Sci Rep202641857149PubTator, text miningPubMed
Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.PLoS One202641801966PubTator, text miningPubMed
Eosinophilic gastroenteritis in a 45-year-old female with epigastric abdominal pain: a rare case report.Ann Med Surg (Lond)202641789234PubTator, text miningPubMed
Regulatory roles of bioactive lipids in vascular homeostasis and remodeling.Med Rev (2021)202641783891PubTator, text miningPubMed

1 to 10 of 1,455

See all 1,455 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/10800

GET https://conductscience.org/api/genes/v1/10800/patents?page=2